Development and Evaluation of a Candidate Inactivated Vaccine Against Bluetongue Virus Serotype 4 (BTV4)
Objectives: Although bluetongue is not a contagious disease, it is easily transmitted and spread by appropriate insect vectors, causing great economic damage. Climate change has led to the fact that vectors and diseases have spread to the top of Northern Europe, causing great economic losses in live...
Saved in:
| Main Authors: | Ljubisa Veljovic, Dimitrije Glisic, Marko Kirovski, Ljiljana Paušak, Vesna Milicevic |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/12/12/1326 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of bluetongue serotype 3 vaccines on probability of viremia and NSAID usage in Dutch dairy cattle herds
by: Reinard R. Everts, et al.
Published: (2025-07-01) -
Impact of BTV-3 Circulation in Belgium in 2024 and Current Knowledge Gaps Hindering an Evidence-Based Control Program
by: Virginie Van Leeuw, et al.
Published: (2025-04-01) -
The MVA-VP2-NS1-2A-NS2-Nt vaccine candidate provides heterologous protection in sheep against bluetongue virus
by: Luis Jiménez-Cabello, et al.
Published: (2025-05-01) -
In Silico Development of a Multi-Epitope Subunit Vaccine against Bluetongue Virus in <i>Ovis aries</i> Using Immunoinformatics
by: Priyansha Raj Sinha, et al.
Published: (2024-10-01) -
Immunogenicity and safety of an inactivated COVID-19 vaccine (CoronaVac®) co-administered with an inactivated enterovirus type 71 vaccine (Inlive®): A phase 4, randomized, controlled trial
by: Yajun Shu, et al.
Published: (2024-12-01)